	Application No.	Applicant(s)	
Notice of Allowability	09/347,175	HOGLE ET AL.	
	Examiner	Art Unit	
	Robert A. Zeman	1645	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.  1. This communication is responsive to 5-17-04.			
2. X The allowed claim(s) is/are 1-2, 4-10, 17-19, 41-44 and 58 now renumbered 1-9, 15-17 and 10-14 respectively.			
3. The drawings filed on <u>01 July 1999</u> are accepted by the Examiner.			
<ul> <li>4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements</li> </ul>			
noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF			
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.  6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached  1) hereto or 2) to Paper No./Mail Date  (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview S Paper No 8), 7. ⊠ Examiner's	nformal Patent Application (PTC Summary (PTO-413), ./Mail Date s Amendment/Comment s Statement of Reasons for Allo	

Application/Control Number: 09/347,175

Art Unit: 1645

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Deirdre E. Sanders on 8-5-2004.

The application has been amended as follows:

## In the claims:

Replaced claims 17 and 19 with the following:

- 17. An isolated and purified fusion molecule consisting of:
  - (a) a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:1-8, amino acids 12-48 of SEQ ID NOS:1-8, amino acids 12-60 of SEQ ID NOS:1-8, SEQ ID NO:9, SEQ ID NO:11, amino acids 12-48 of SEQ ID NO:11, amino acids 12-60 of SEQ ID NO:11, SEQ ID NOS:15-20, SEQ ID NO:25, and fragments thereof that form a coil; and
  - (b) at least one binding moiety.
- 19. An isolated and purified molecule comprising:
- (a) a polypeptide consisting of an amino acid sequence of amino acids 12-88 of the hepatitis delta antigen (HDAg), or a fragment thereof which forms a coiled coil oligomer when

Page 3

Application/Control Number: 09/347,175

Art Unit: 1645

contacted with a peptide consisting of amino acids 12 to 88 of HDAg or a fragment thereof that forms a coil; and

(b) a nuclear localization signal.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert A. Zeman August 5, 2004 LYNETTE R. F. SMITH SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600